Targeting Melanoma

Langreth, Robert
November 2007
Forbes Asia;11/12/2007, Vol. 3 Issue 19, p128
The article looks into the development and testing of melanoma drugs. Pfizer's drug tremelimumab and Bristol-Myers Squibb's ipilimumab are antibodies to a protein called cytotoxic T-lymphocyte antigen-4 (CTLA-4) that acts as an emergency brake to prevent killer T cells from attacking healthy tissue. Both Pfizer and Medarex subsequently produced human antibodies to CTLA-4 and began testing them in patients. In 2005, Bristol-Myers Squibb paid Medarex for the success of Medarex's antibody.


Related Articles

  • Bristol-Myers Squibb and Medarex further melanoma collaboration.  // PharmaWatch: Biotechnology;December2004, Vol. 3 Issue 12, p16 

    Reports Medarex Inc.'s worldwide collaboration with Bristol-Myers Squibb Co. to develop and commercialize an investigational anticancer antibody, MDX-010, as well as continuing development of their co-developed melanoma peptide vaccine. Clinical development for the treatment of metastatic...

  • Dual fronts poised to transform melanoma therapy. Mullard, Asher // Nature Reviews Drug Discovery;May2011, Vol. 10 Issue 5, p325 

    The article offers information related to drug development for melanoma. It says that the cytotoxic T lymphocyte antigen 4 (CTLA4) exhibited by the ipilimumab (Yervoy) developed by Bristol-Myers Squibb Co. (BMS) effectively releases the brakes and unleashing T cells on tumours of the immune...

  • Pfizer Halts Trial, Medarex Takes Hit.  // Bioworld Week;4/7/2008, Vol. 16 Issue 14, p1 

    The article reports that market shares of Medarex Inc. in the U.S. has dropped down as partner Pfizer Inc., the largest drugmaker worldwide, stopped a Phase II trial of tremelimumab, an antibiotic for melanoma treatment. Accordingly, the halted Pfizer trial could indicate bad news for ipilimumab...

  • Drug development: Try and try again. Scudellari, Megan // Nature;12/4/2014 Supplement, Vol. 516 Issue s7529, pS4 

    The article discuses challenges in drug development for liver cancer by the drug companies and highlights the success of various approaches. Clinical trials of pharmaceutical companies such as Eli Lilly, Bristol-Myers Squibb and Pfizer are discussed. Failure of drug trials in hepatocellular...

  • Drugs in Clinical Development for Melanoma.  // Pharmaceutical Medicine - New Zealand;2012, Vol. 26 Issue 3, p172 

    The article focuses on new drugs in development intended for the treatment of melanoma. Two immunotherapies have been initially developed and approved which are Zelboraf, a B-Raf enzyme inhibitor vermurafenib from Roche, and Yervoy, an anti-CTLA-4 monoclonal antibody ipilimumab from...

  • Medarex Shares Take Hit Amid Pfizer's Halted Melanoma Trial. Hollingsworth, Catherine // BioWorld Today;4/3/2008, Vol. 19 Issue 65, p1 

    This article reports on the impact of the decision of Pfizer Inc. to halt a Phase III trial of potential melanoma treatment tremelimumab on the shares of its partner, Medarex. The drug maker has an existing patent licensing agreement with Medarex, and the latter is expected to gain royalties if...

  • Untitled.  // MondayMorning;3/8/2010, Vol. 18 Issue 9, p21 

    The article focuses on experimental drug apixaban developed by Pfizer Inc. and Bristol-Myers Squibb Co., which proved to be better for treatment in a late stage knee surgery in New York. Apixaban is one of new oral anticoagulants expected to replace the lovenox. It is stated that experimental...

  • First PD-1 inhibitor breezes across finish line. Sheridan, Cormac // Nature Biotechnology;Sep2014, Vol. 32 Issue 9, p847 

    The article offers information on the approval for Opdivo (nivolumab), a fully human IgG4 antibody that inhibits programmed death 1 (PD-1), for treating unresectable melanoma, developed by Ono Pharmaceutical and partner Bristol-Myers Squibb (BMS) in Japan under the Prescription Drug User Fee...

  • Ipilimumab: Melanoma and beyond. Patel, Vishal; Gandhi, Hardik; Upaganlawar, Aman // Journal of Pharmacy & Bioallied Sciences;Oct-Dec2011, Vol. 3 Issue 4, p546 

    The article reports on the continuing treatment of metastatic melanoma with ipilimumab after its approval by the Food and Drug Administration in the U.S. The pharmaceutical firm Bristol-Myers Squibb Co. has developed the ipilimumab, a fully human monoclonal antibody, to prevail the shortcomings...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics